OCAT had just $3.5M in the till as of March 31st, against a burn rate of ~$8M per quarter. So they are continuing their past practice of continuous stock sales, I assume against some sort of shelf offering, to stay afloat.
If their "pluripotent" stem cells story is that compelling--off of three, apparently successful Phase 1 trials in parallel--do you know why they haven't gone out and floated a large offering?
Market Data 
Markets 
AI
